Elarofiban

CAS No. 198958-88-2

Elarofiban( —— )

Catalog No. M34233 CAS No. 198958-88-2

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 922 In Stock
10MG 1226 In Stock
25MG 1853 In Stock
50MG 2437 In Stock
100MG 3283 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Elarofiban
  • Note
    Research use only, not for human use.
  • Brief Description
    Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.
  • Description
    Elarofiban (RWJ-53308) is a nonpeptide, orally active fibrinogen receptor antagonist. Elarofiban has the potential for platelet mediated thrombotic disorders research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    198958-88-2
  • Formula Weight
    416.51
  • Molecular Formula
    C22H32N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](NC(=O)[C@H]1CN(C(CCC2CCNCC2)=O)CCC1)(CC(O)=O)C=3C=CC=NC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Judith H. Cohen, et al. A Practical Synthesis of the Platelet Fibrinogen Antagonist, Elarofiban. Organic Process Research & Development 2003, 7, 866-872.
molnova catalog
related products
  • GSK-3008348 hydrochl...

    GSK-3008348 hydrochloride is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

  • CASIN

    CASIN is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).

  • Bersanlimab

    Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1), demonstrating anticancer properties and applicable for studying relapsed/refractory multiple myeloma.